It scored not one, but two beats on analyst estimates for its third-quarter performance. This, despite a slight year-over-year decline in adjusted profitability. Revenue for Omnicell in its third ...
Omnicell OMCL is advancing toward the industry-defined vision of Autonomous Pharmacy by leveraging automation and advanced services across its cloud-based platform. The strength of the company’s ...
In the preceding three months, 7 analysts have released ratings for Omnicell (NASDAQ:OMCL), presenting a wide array of perspectives from bullish to bearish. The table below offers a condensed view of ...
Omnicell’s OMCL fourth-quarter 2024 performance was driven by its long-term development strategy, such as innovative solutions, expansion into new markets, strategic partnerships and procurement of ...
Omnicell (OMCL) stock jumps as KeyBanc Capital Markets upgrades the firm, citing a "super-cycle" of growth driven by its new ...
Piper Sandler upgraded its rating of Omnicell (NASDAQ:OMCL) to Overweight with a price target of $39.00, changing its price target from $70.00 to $39.00. Shares of Omnicell are trading up 1.81% over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback